Drugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities

References

• Weiss R, Caprio S, Trombetta M, et al. Beta-cell function across the spectrum of glucose tolerance in obese youth. Diabetes. 2005;54:1735–1743.
   PubMed Web of Science ®Google Scholar
• Elder DA, Hornung LN, Herbers PM, et al. Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. J Pediatr. 2015;166:672–678.
   PubMed Web of Science ®Google Scholar
• Farshchi A, Nikfar S, Seyedifar M, et al. Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. J Pharm Pharm Sci. 2013;16:99–114.
   PubMed Web of Science ®Google Scholar
• Faghihi T, Radfar M, Barmal M, et al. A randomized, placebo-controlled trial of selenium supplementation in patients with type 2 diabetes: effects on glucose homeostasis, oxidative stress, and lipid profile. Am J Ther. 2014;21:491–495. DOI:10.1097/MJT.0b013e318269175f
   PubMed Web of Science ®Google Scholar
• Bahadar H, Mostafalou S, Abdollahi M. Growing burden of diabetes in Pakistan and the possible role of arsenic and pesticides. J Diabetes Metab Disord. 2014;13:117. DOI:10.1186/s40200-014-0117-y
   PubMedGoogle Scholar
• Mostafalou S, Abdollahi M. Pesticides and human chronic diseases: evidences, mechanisms, and perspectives. Toxicol Appl Pharmacol. 2013;268:157–177.
   PubMed Web of Science ®Google Scholar
• Mohseni Salehi Monfared SS, Larijani B, Abdollahi M. Islet transplantation and antioxidant management: a comprehensive review. World J Gastroenterol. 2009;15:1153–1161.
   PubMed Web of Science ®Google Scholar
• Tabatabaei-Malazy O, Nikfar S, Larijani B, et al. Influence of ascorbic acid supplementation on type 2 diabetes mellitus in observational and randomized trials: a systematic review and mata-analysis. J Pharm Pharm Sci. 2014;17:554–582.
   PubMedGoogle Scholar
• Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146(5):693–700.
   PubMed Web of Science ®Google Scholar
• Dabelea D, Bell RA, D’Agostino RB Jr, et al.; Writing Group for the Search for Diabetes in Youth Study Group. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716–2724.
   PubMed Web of Science ®Google Scholar
• Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311:1778–1786.
   PubMed Web of Science ®Google Scholar
• Laffel L, Svoren B, Wolfsdorf JI, et al. Epidemiology, presentation, and diagnosis of type 2diabetes mellitus in children and adolescents. 2016 [updated 2015 Mar 14]. Available from: www.UpToDate.com
   Google Scholar
• American diabetes association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl. 1): S8–S16. DOI:10.2337/dc15-S005
   PubMed Web of Science ®Google Scholar
• Awa WL, Fach E, Krakow D, et al. Type 2 diabetes from pediatric to geriatric age: analysis of gender and obesity among 120,183 patients from the German/Austrian DPV database. Eur J Endocrinol. 2012;167:245–254.
   PubMed Web of Science ®Google Scholar
• Caprio S. Insulin resistance in childhoodobesity. J PediatrEndocrinolMetab. 2002;15(suppl 1):487–492.
   Google Scholar
• Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of high body mass index in US children and adolescents, 2007–2008. JAMA. 2010;303:242–249.
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA. 2012;307:483–490.
   PubMed Web of Science ®Google Scholar
• Li C, Ford ES, Zhao G, et al. Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005–2006. Diabetes Care. 2009;32:342–347.
   PubMed Web of Science ®Google Scholar
• Foster GD, Linder B, Baranowski T, et al.; HEALTHY Study Group. A school-based intervention for diabetes risk reduction. N Engl J Med. 2010;363(5):443–453. DOI:10.1056/NEJMoa1001933
   PubMed Web of Science ®Google Scholar
• Urakami T, Kubota S, Nitadori Y, et al. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care. 2005;28:1876–1881.
   PubMed Web of Science ®Google Scholar
• Forsén T, Eriksson J, Tuomilehto J, et al. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med. 2000;133:176–182.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2014 National Diabetes Statistics Report. [cited 2016 Apr 29]. Available from: http://www.cdc.gov/diabetes/data/statistics/2014StatisticsReport.html
   Google Scholar
• Safavi M, Foroumadi A, Abdollahi M. The importance of synthetic drugs for type 2 diabetes drug discovery. Expert Opin Drug Discov. 2013;8:1339–1363. DOI:10.1517/17460441.2013.837883
   PubMed Web of Science ®Google Scholar
• Radfar M, Abdollahi M. Pharmacotherapy in endocrinology: diabetes, obesity, and hyperlipidemia-review article. Iran J Publ Health. 2014;43(suppl 1):49–63.
   Google Scholar
• Tabatabaei-Malazy O, Atlasi R, Larijani B, et al. Trends in publication on evidence- based antioxidative herbal medicines in management of diabetic nephropathy. J Diabetes Metab Disord. 2016;15:1. DOI:10.1186/s40200-016-0221-2
   PubMed Web of Science ®Google Scholar
• Farzaei MH, Rahimi R, Farzaei F, et al. Traditional medicinal herbs for the management of diabetes and its complications: an evidence-based review. Int J Pharmacol. 2015;11:874–887.
   Web of Science ®Google Scholar
• Tabatabaei-Malazy O, Larijani B, Abdollahi M. Targeting metabolic disorders by natural products. J Diabetes Metab Disord. 2015;14:57. DOI:10.1186/s40200-015-0184-8
   PubMedGoogle Scholar
• Hood KK, Beavers DP, Yi-Frazier J, et al. Psychosocial burden and glycemic control duringthe first 6 years of diabetes: results from theSEARCH for Diabetes in Youth Study. J AdolescHealth. 2014;55:498–504.
   Google Scholar
• American diabetes association. Children and adolescents. Diabetes Care. 2015;38(Suppl. 1): S70–S76. DOI:10.2337/dc15-S014
   Google Scholar
• Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131:364–382.
   PubMed Web of Science ®Google Scholar
• Zeitler P, Fu J, Tandon N, et al. International society for pediatric and adolescent diabetes. ISPAD clinical practice consensus guidelines 2014.Type 2 diabetes in the child and adolescent. Pediatr Diabetes. 2014;15(Suppl 20):26–46. DOI:10.1111/pedi.12179
   PubMed Web of Science ®Google Scholar
• Onge ES, Miller SA, Motycka C, et al. A review of the treatment of type 2 diabetes in children. J Pediatr Pharmacol Ther. 2015;20:4–16. DOI:10.5863/1551-6776-20.1.4
   PubMedGoogle Scholar
• Ahern JAH, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes. 2002;3:10–15.
   PubMedGoogle Scholar
• Laffel L, Svoren B, Wolfsdorf JI, et al. Management of type 2 diabetes mellitus in children and adolescents. 2016 [updated 2014 Jun 10]. Available from: www.UpToDate.com
   Google Scholar
• Sellers EA, Dean HJ. Short-term insulin therapy in adolescents with type 2 diabetes mellitus. J PediatrEndocrinolMetab. 2004;17:1561–1564.
   Web of Science ®Google Scholar
• Dileepan K, Feldt MM. Type2 diabetes mellitus in children and adolescents. Pediatrics in Review. 2013;34:541–548.
   PubMedGoogle Scholar
• Vaidyanathan J, Choe S, Sahajwalla CG. Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective. J Pharm Sci. 2012;101:1659–1671. DOI:10.1002/jps.23085
   PubMed Web of Science ®Google Scholar
• Jones KL, Park JS, Arslanian S, et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002;25:89–94.
   PubMed Web of Science ®Google Scholar
• Zeitler P, Hirst K, Pyle L, et al., TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–2256.
   PubMed Web of Science ®Google Scholar
• TODAY Study Group. Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. Diabetes Care. 2013;36:1765–1771. DOI:10.2337/dc12-2390
   PubMed Web of Science ®Google Scholar
• TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care. 2013;36:1749–1757. DOI:10.2337/dc12-2393
   PubMed Web of Science ®Google Scholar
• Mauras N, DelGiorno C, Hossain J, et al. Metformin use in children with obesity and normal glucose tolerance: effects on cardiovascular markers and intrahepatic fat. J PediatrEndocrMetab. 2012;25:33–40.
   Google Scholar
• Boland CL, Harris JB, Harris KB. Pharmacological management of obesity in pediatric patients. Ann Pharmacother. 2015;49:220–232. DOI:10.1177/1060028014557859
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J ClinEndocrinolMetab. 2006;91:2074–2080.
   PubMed Web of Science ®Google Scholar
• Burgert TS, Duran EJ, Goldberg-Gell R, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008;9:567–576.
   PubMed Web of Science ®Google Scholar
• Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double blind, placebo-controlled trial. J PediatrEndocrinoMetab. 2008;21:339–348.
   Google Scholar
• Clarson CL, Mahmud FH, Baker JE, et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine. 2009;36:141–146.
   PubMed Web of Science ®Google Scholar
• Wilson DM, Abrams SH, Aye T, et al. Metformin extended release treatment of adolescent obesity. Arch PediatrAdolesc Med. 2010;164:116–123.
   PubMed Web of Science ®Google Scholar
• Wiegand S, l’Allemand D, Hübel H, et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol. 2010;163:585–592.
   PubMed Web of Science ®Google Scholar
• Rezvanian H, Hashemipour M, Kelishadi R, et al. A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity. World J Pediatr. 2010;6:317–322.
   PubMed Web of Science ®Google Scholar
• Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. EndocrinolMetab. 2013;98:322–329.
   PubMed Web of Science ®Google Scholar
• Bouza C, Lopez-Cuadrado T, Gutierrez-Torres FL, et al. Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis. Obes Facts. 2012;5:753–765.
   PubMed Web of Science ®Google Scholar
• Brufani C, Crinò A, Fintini D, et al. Systematic review of metformin use in obese nondiabetic children and adolescents. Horm Res Paediatr. 2013;80:78–85. DOI:10.1159/000353760
   PubMed Web of Science ®Google Scholar
• Christensen ML, Meibohm B, Capparelli EV, et al. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol. 2005;45:1137–1144.
   PubMed Web of Science ®Google Scholar
• Summaries of Medical and Clinical Pharmacology Reviews. [Updated 2015 Jan 6]. Avaialble from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm161894.htm
   Google Scholar
• Cali AMG, Pierpont BM, Taksali SE, et al. Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study. Obesity. 2011;19:94–99.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191–1201. DOI:10.1001/archinternmed.2010.207
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. [cited 2016 Apr 1]. Available from: http://www.fda.gov/drugs/drugsafety/ucm259150.htm
   Google Scholar
• Loke YK, Singh S, Furberg C. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–39.
   PubMed Web of Science ®Google Scholar
• Gottshalk M, Danne T, Vlajnic A, et al. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes. Diabetes Care. 2007;30:790–794.
   PubMed Web of Science ®Google Scholar
• Culler FL, McKean LP, Buchanan CN, et al. Glipizide treatment of patients with cystic fibrosis and impaired glucose tolerance. J PediatrGastroenterolNutr. 1994;18:375–378.
   PubMed Web of Science ®Google Scholar
• Becker M, Galler A, Raile K. Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3). Pediatrics. 2014;133:e775–9.
   Google Scholar
• Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 2013;167:355–360. DOI:10.1001/jamapediatrics.2013.1045
   PubMed Web of Science ®Google Scholar
• Kelly AS, Metzig AM, Rudser KD, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring). 2012;20:364–370. DOI:10.1038/oby.2011.337
   PubMed Web of Science ®Google Scholar
• Safety and efficacy study of exenatide once weekly in adolescents with type 2 diabetes. [updated 2016 Sep 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT01554618
   Google Scholar
• Klein DJ, Battelino T, Chatterjee DJ, et al.; NN2211-1800 Study Group. Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes TechnolTher. 2014;16:679–687. DOI:10.1089/dia.2013.0366
   PubMed Web of Science ®Google Scholar
• Novo Nordisk A/S. A randomized, double-blind, placebo controlled trial to assess safety, tolerability and pharmacokinetics of liraglutide in obese adolescent subjects aged 12-17 years (identifier: NCT01789086). [cited 2014 May 28]. Available from: http://clinicaltrials.gov/ct2/show/NCT01789086
   Google Scholar
• Evaluation of the blood levels of the drug (Lixisenatide), the plasma glucose levels and safety in pediatric and adult patients with type 2 diabetes. [updated 2014 May 22]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01572649
   Google Scholar
• Pharmacokinetics, pharmacodynamics, and safety of Alogliptin in children, adolescents and adults with type 2 diabetes mellitus. [updated 2015 Jan 26]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00957268
   Google Scholar
• Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin concentrations/levels in pediatric subjects with T2DM. [updated 2015 May 27]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01525225
   Google Scholar
• A study to assess the pharmacokinetics, safety and tolerability of Sitagliptin in adolescents (0431-081). [updated 2015 Aug 7]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00730275
   Google Scholar
• Tucker ME FDA warns of heart failure risk with two diabetes drugs. Medscape Medical News. [updated 2016 Apr 5]. Available from: http://www.medscape.com/viewarticle/861514
   Google Scholar
• Kentrup H, Bongers H, Spengler M, et al. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. Eur J Pediatr. 1999;158:455–459.
   PubMed Web of Science ®Google Scholar
• McCulloch DK, Nathan DM, Mulder JE Management of persistent hyperglycemia in type 2 diabetes mellitus. 2016 [updated 2016 Jun 10]. Available from www.UpToDate.com
   Google Scholar
• Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res ClinPract. 2014;104:297–322. DOI:10.1016/j.diabres.2014.02.014
   PubMed Web of Science ®Google Scholar
• Pharmacokinetic study of Cycloset® 0.8 mg tablets in children and adolescent type 2 diabetes mellitus subjects [updated 2016 Apr26]. 81. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02078440
   Google Scholar
• Colesevelam pediatric type 2 diabetes mellitus study (WELKidDM) [updated 2016 Apr 14]. 88. Available from: https://clinicaltrials.gov/ct2/show/NCT01258075
   Google Scholar
• Mechanisms of glucose lowering effect of Colsevelam Hcl [updated 2012 Oct 10]. 86. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00596427
   Google Scholar
• Ramkumar S, Tandon N. Type 2 diabetes mellitus in children and youth. Indian J Pediatr. 2013;80(Suppl 1):S87–94. DOI:10.1007/s12098-013-0962-6
   Google Scholar
• TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1735–1741.
   PubMed Web of Science ®Google Scholar
• Laffel L, Svoren B, Wolfsdorf JI, Hoppin AG. Comorbidities and complications of type 2 diabetes mellitus in children and adolescents. 2016 [updated 2016 Mar 14]. Available from www.UpToDate.com
   Google Scholar
• Meyers RS, Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clinical Therapeutics. 2011;33:1331–1356.
   PubMed Web of Science ®Google Scholar
• Schaefer F, Litwin M, Zachwieja J, et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertense. 2011;29:2484–2490.
   PubMed Web of Science ®Google Scholar
• Lurbe E, Agabiti-Rosei E, Cruickshank K, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016;34:1887–1920. DOI:10.1097/HJH.0000000000001039
   PubMed Web of Science ®Google Scholar
• Elliott WJI, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–207.
   PubMed Web of Science ®Google Scholar
• New pediatric labeling information database. [cited 2016 Oct 16]. Available from: www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm
   Google Scholar
• Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3–10.
   PubMed Web of Science ®Google Scholar
• Springer SC, Silverstein J, Copeland K, et al.; American Academy of Pediatrics. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics. 2013;131. e648–64. DOI:10.1542/peds.2012-3496
   Google Scholar
• Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis. 2006;47:927–946.
   PubMed Web of Science ®Google Scholar
• Marcovecchio ML, Woodside J, Jones T, et al.; AdDIT Investigators. Adolescents type 1 diabetes cardio-renal intervention trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments. Diabetes Care. 2014;37:805–813.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics (AAP) recommendations for manging newly diagnosed type 2 diabetes in children and adolescents. Comorbidities: microalbuminuria. [cited 2016 Oct 24]. Available from: http://www.ndei.org/AAP-type-2-diabetes-children-adolescents-2013.aspx.html#microalbuminuria
   Google Scholar
• Kershnar AK, Daniels SR, Imperatore G, et al. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr. 2006;149:314–319.
   PubMed Web of Science ®Google Scholar
• TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1758–1764. DOI:10.2337/dc12-2388
   PubMed Web of Science ®Google Scholar
• Donaghue KC, Wadwa RP, Dimeglio LA, et al.; International Society for Pediatric and Adolescent Diabetes. ISPAD clinical practice consensus guidelines 2014. Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes. 2014;15(Suppl 20):257–269. DOI:10.1111/pedi.12180
   PubMed Web of Science ®Google Scholar
• Prabhakar PK, Kumar A, Doble M. Combination therapy: a new strategy to manage diabetes and its complications. Phytomedicine. 2014;21:123–130. DOI:10.1016/j.phymed.2013.08.020
   PubMed Web of Science ®Google Scholar